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Abstract 
Biological therapies for the management of immune mediated inflammatory diseases such as 
rheumatoid arthritis have proven to be extremely successful in recent years. Despite these successes, 
even the most effective of therapies do not lead to cure. Why chronic inflammation persists 
indefinitely within the rheumatoid synovium despite an absence of continuous stimulation, and why 
some patients with early synovitis progress to persistent disease whilst others do not, has remained 
unexplained. In contrast to the paradigm that stromal cells are biochemically active but 
immunologically passive, there is now growing evidence that stromal components from the 
rheumatoid synovium play a crucial part in the immunopathology of rheumatoid arthritis. Stromal 
cells play a central role in the transformation of an acute, resolving to a chronic inflammatory process, 
and to the persistence of synovial inflammation and joint destruction through a variety of immune 
mechanisms. Therapeutic manipulation of the stroma is a largely unexplored, yet potentially vital area 
of research. Targeting pathogenic stromal cells has the potential to provide a cure for chronic 
inflammatory disorders such as rheumatoid arthritis.   
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1.0 Introduction 
Inflammation is an intrinsic, biological response that occurs to protect organisms against 
harmful stimuli. At a cellular level, inflammation is characterised by an influx of leukcocytes into 
damaged or infected tissue. The duration, type and magnitude of leukocyte influx is controlled by 
cytokine and chemokine gradients. For an inflammatory response to resolve completely, these 
gradients must be removed, and leucocytes must be cleared from the site of pathology, either by 
migration out of the site, or via apoptosis (1). 
Episodes of acute inflammation most often occur in the context of infection; these episodes 
are transient, often self-limiting and are followed by a phase of tissue repair leading to health. 
Chronic, persistent inflammation in contrast often occurs in the absence of a pathogen, and in the 
case of autoimmune diseases such as rheumatoid arthritis, may persist indefinitely even in the 
absence of a harmful external stimuli.  
The current and established pharmacological management of most autoimmune pathologies 
aims to dampen the persistent, harmful inflammatory response in the tissue affected. This approach 
of minimising damage and progression of disease is however suboptimal. The optimal approach is to 
reverse the fundamental pathological process.  
Our understanding of the role that stromal cells play in inflammation has changed 
considerably. Stromal cells, in particular fibroblasts, are emerging as key drivers in the genesis of 
tissue specific inflammation, modulation of tissue microenvironments, transformation from acute to 
chronic inflammation and persistence of inflammation through a multitude of immune-mediated 
modalities, particularly in rheumatoid arthritis (2).  These discoveries raise the possibility that stromal 
cells may turn out to be novel therapeutic targets in the discovery of a cure for chronic inflammatory 
diseases. 
This review aims to highlight the role that fibroblasts, a key cellular component of the 
stroma, play in the genesis and persistence of chronic inflammation in rheumatoid arthritis and to 
provide an insight into how currently available biologic agents modulate stromal cell function. It will 
also outline possibilities for novel stromal cell targets, which may be beneficial in future therapies for 
rheumatoid arthritis. 
  
2.0 The stroma 
Tissue stroma comprises the subendothelial basement membrane and the underlying connective 
tissue containing stromal cells such as pericytes, fibroblasts and organ specific stromal cells 
(astrocytes, hepatocytes) and epithelial cells as well as adipocytes (2). The extracellular matrix that 
lies between stromal cells is comprised mainly of gylcosaminoglycans and proteoglycans. Lymphatic 
and blood vessels and nervous tissue is interspersed throughout the stroma. It is through this matrix 
that leucocytes migrate to and from an area of inflammation (3). Considerable effort has been 
expended in targeting vascular endothelial cells in cancer and inflammation. While new anti-
angiogenic agents have shown promise in some cancers, their application to autoimmune diseases 
remain disappointing  
 
2.1 Fibroblast biology 
The fibroblast is the most common cell type within the stroma (4). Fibroblasts are identified 
by their spindle-shape morphology, expression of interstitial collagens (types I and III) and their 
adherence to plastic in culture (5). Fibroblasts express numerous markers which aid in their 
identification (6) (Table 1). However None of these markers is highly specific to fibroblasts, nor is any 
marker reliably present in all fibroblasts (7). Because of this, there has been until recently a lack of 
information on the origin, function and role of fibroblasts in disease (8).  
Mesenchymal Stromal cells (MSCs) are multipotent cells, which are currently undergoing 
extensive investigation for use in tissue repair. They share common cell surface markers, morphology 
and immunologic properties with fibroblasts (9). It is currently, although not exclusively accepted, 
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that MSCs and fibroblasts are distinct cell types, set apart by the ability of MSCs to differentiate into 
any mesodermal tissue (10) and the discovery that fibroblasts are not always mesodermal in origin. 
For example fibroblasts in the head and neck arise from the ectoderm through a process termed 
epithelial to mesenchymal transition (EMT) (11). 
Under physiological conditions, the stroma functions primarily to provide structure by 
synthesising and remodelling the extracellular matrix (ECM). Fibroblasts synthesise type I, type III and 
type V collagen, and fibronectin (12) but also have a role ECM degradation via matrix 
metalloproteinases (MMPs) (13). Thus fibroblasts have prime responsibility for the maintenance of 
ECM homeostasis by regulating matrix turnover (7). Fibroblasts also help in maintaining biochemical 
homeostasis between adjacent epithelial cells (7) and have a key role in tissue development, 
differentiation and repair (including fibrosis) (14). 
Of the cells that comprise the stroma, the fibroblast has been most implicated in generating 
and directing both the innate and adaptive immune response in health and disease (14). Synovial 
fibroblasts from patients with rheumatoid arthritis have provided key information on how the stroma 
is responsible for persistence of chronic inflammation. This is discussed in detail below. 
 
Table 1: Fibroblast markers 
Adapted from Kalluri and Zeisberg (2006) (7) and Filer (2013) (15) *of particular significance as a 
possible therapeutic target 
 
2.2 Pathogenic Stroma 
Stromal tissue has been shown to play a functional role in three chronic pathological states: 
malignant disease, tissue fibrosis and chronic inflammation (16). In all of these conditions, stromal 
cells have been observed to undergo specific, disease dependent phenotypic and functional changes 
which promote the disease state (17). In malignancy for example, in addition to production of the 
Marker Function Fibroblast subtype Expressed elsewhere 
Vimentin 
Intermediate filament associated 
protein 
Miscellaneous 
Endothelial cells, 
myoepithelial cells, neurons 
α-SMA 
Intermediate filament associated 
protein 
Myofibroblasts 
Vascular smooth muscle cells, 
pericytes, myoepithalial cells 
Desmin 
Intermediate filament associated 
protein 
Skin fibroblasts 
Muscle cells, vascular smooth 
muscle cells 
FSP1 
Intermediate filament associated 
protein 
Miscellaneous Invasive carcinoma cells 
Discoidin-domain 
receptor 2 
Collagen receptor Cardiac fibroblasts Endothelial cells 
FAP* Serine protease Activated fibroblasts Activated melanocytes 
α1β1 integrin Collagen receptor Miscellaneous Monocytes, endothelial cells 
Prolyl 4-hydroxylase Collagen biosynthesis Miscellaneous 
Endothelial cells, cancer cells, 
epithelial cells 
Pro-collagen1α2 Collagen-1 biosynthesis Miscellaneous Osteoblasts, chondroblasts 
CD248* Unknown Miscellaneous Pericytes 
VCAM-1 Cell adhesion Miscellaneous Activated endothelial cells 
gp38* Invasiveness in cancer Miscellaneous 
Alveolar cells, podocytes, 
endothelial cells, neurons 
Cadherin-11* Homotypic adhesion Miscellaneous Nil 
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non-tumour extracellular matrix that facilitates growth of solid tumours, the stroma has been shown 
to be a key driver of tumour progression by inhibiting apoptosis of malignant cells in breast carcinoma 
(18). Fibroblast activation protein (FAP), a serine protease that is selectively expressed in reactive 
fibroblasts of epithelial cancers has also been noted to have a pathogenic role in malignancy (19). FAP 
blockade in mice models of pancreatic ductal carcinoma has been shown to induce hypoxic necrosis 
of tumour and stromal cells in a process that is dependent on Interferon gamma (IFNγ) and TNF alpha 
(TNFα) (20). In addition to these effects, reactive stroma and cancer associated fibroblasts are also 
known to facilitate tumourigenesis and metastasis via generation of oncogenic signals (21) and 
promotion of angiogenesis (22).  
 
2.3 Acute inflammation 
During episodes of acute inflammation, vascular endothelial cells (ECs) are responsible for 
the immediate recruitment of specific leucocyte subsets to an area of acute pathology by expressing 
specific adhesion molecules and chemokines in response to biochemical signals generated by 
inflammatory/infectious/traumatic tissue injury (23-25). In the acute inflammatory response to 
infection, tissue resident macrophages may release cytokines such as IL-1 or TNFα. Along with 
bacterial components, and activated complement fragments, these cytokines stimulate vascular ECs 
to express adhesion molecules that interact with surface presented chemokines or other mediators, 
that, in turn, activate leukocyte integrins (2). The types and patterns of adhesion receptors expressed 
as well as the chemokine gradients are determined by the nature of the stimulus driving the 
inflammatory response (26-30). For example, αMβ2-integrin binds intracellular adhesion molecule 
1(ICAM-1) to stabilize adhesion and supports migration of neutrophils to the site of acute 
inflammation (2). Capturing peripheral blood leukocytes (PBLs) to an area of chronic inflammation in 
contrast, requires α4β1-integrin to bind to vascular cell adhesion molecule 1 (VCAM-1), a process 
which is stabilised by the chemokine CXCR3 (27). 
Whilst the EC is the principal cell type controlling leukocyte migration into an area of acute 
inflammation, stromal components are known to have an important role in the regulation of this 
response. When co-cultured ECs and fibroblasts are exposed to the pro-inflammatory cytokines TNFα 
and IFNγ, fibroblasts reduce lymphocyte migration in an IL-6 dependent fashion; these effects are not 
seen in the absence of TNFα/IFNγ (31), suggesting that healthy fibroblasts play an 
immunomodulatory role by preventing inappropriate recruitment of leukocytes to areas of acute 
inflammation. This is in contrast to the pathogenic role that fibroblasts play in chronic inflammation 
 
2.4 The recruitment postcode 
The specific combination of receptors, chemokines and other agents driving leukocyte 
transmigration is often referred to as the recruitment postcode (2). When fibroblasts and ECs are co-
cultured, alterations in genotype are observed in both cells. These changes are dependent on the 
anatomical source of the fibroblasts (32). The phenotype of the fibroblast itself however, is also 
altered by inflammatory stimuli (8, 33). It is therefore probable that the fibroblast, rather than the 
endothelial cell is the primary protagonist in modulating tissue-specific, stimulus-specific 
inflammatory responses through control of endothelial cell function. 
 
2.5 Fibroblast activation 
Fibroblast activation refers to the process by which fibroblasts rapidly produce cytokines, 
chemokines, prostanoids, large amounts of ECM proteins (both constituents and degradation 
proteins) and express α-smooth-muscle actin in response to tissue injury (7, 17, 34). Activated 
fibroblasts are found in damaged, inflamed or healing tissue. These activated cells regulate the 
behaviour of leukocytes that are recruited to damaged tissue. CD40-CD40 ligand interactions is known 
to regulate this process by activating the nuclear factor (NF)-κB family of transcription factors, leading 
to myofibroblast production of large amounts of IL-6, IL-8, cycloxygenase-2 (COX-2) and hyaluronan 
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(35, 36). Cytokines and chemokines produced by fibroblasts appear be specific to the type of injurious 
stimulus and the anatomical site of pathology (15).  
 
3.0 The stroma in chronic inflammation 
Chronic inflammation is characterised by its persistence, predilection for certain anatomical 
sites and propensity to be associated with significant disease related comorbidity including cancer, 
infection and diseases affecting the cardiovascular system and bone. Inflammation can only resolve if 
leukocyte recruitment, accumulation and survival is outweighed by leukocyte emigration and 
apoptosis at the site of inflammation. Why chronic inflammation fails to completely resolve, even 
after removal of injurious stimuli has, until relatively recently been poorly understood. 
 
3.1 Accumulation of epigenetic changes and stability of the inflamed microenvironment 
The structural composition of inflammatory sites at a microscopic level shows that the tissue 
microenvironment is defined largely by resident stromal cells such as fibroblasts (17). In chronic 
inflammation and during tissue fibrosis, fibroblasts maintain a state of permanent activation even 
once the initial stimulus has regressed. This activated phenotype persists until cells reach senescence 
(7). As with alterations in fibroblast phenotype by anatomical site, activated fibroblasts from diseased 
tissue (kidney, synovium, lung parenchyma) are also distinct in their phenotype and immune 
properties compared to fibroblasts from the same site in health (37-39). Furthermore, persistent 
activation of fibroblasts is stable; they maintain their distinctive phenotype even in tissue culture and 
in the absence of external stimulation and leucocytes (17). These findings indicate that permanently 
activated fibroblasts create inflamed tissue microenvironments that are intrinsically imprinted and 
stable (17). The molecular basis of persistent fibroblast activation in chronic inflammation is poorly 
understood. However recent evidence suggests that stable epigenetic modifications of the fibroblast 
genome (e.g. DNA hypomethylation) in response to inflammatory insults may be an important 
contributing factor (40, 41). Repeated episodes of acute, non-resolving inflammation may cause 
multiple epigenetic changes in the genome of the fibroblast, having a synergistic effect on promotion 
of stability of the activated, site-specific phenotype.  
 
3.2 Recruitment of leukocytes to sites of chronic inflammation 
Evidence from co—culture models suggests that physiological stromal tissue, which is not 
imprinted with an inflammatory phenotype, can become immunomodulatory, inhibiting and 
regulating leukocyte migration through ECs via IL-6 cytokine signalling (31). In contrast to fibroblasts 
from healthy tissue, rheumatoid arthritis synovial fibroblasts (RA-SFs) activate co-cultured ECs and 
support recruitment and migration of neutrophils and lymphocytes in vitro in the absence of external 
stimuli (32, 42-44). Adhesion of infiltrating leukocytes to stromal tissue appears to be mediated by 
fibroblast-derived chemokines (42). Neutrophil activation occurs when CXCR2 binds CXCL5, 
lymphocyte activation occurs when CXCR4 binds to CXCL12, also known as stromal derived factor-1 
(SDF-1) (32, 42, 43). For both lymphocytes and neutrophils, recruitment is dependent on IL-6 
generated in the co-culture period (32, 42, 43).  
Along with stimulation of adhesion and leukocyte activation, inflammatory fibroblasts from 
the rheumatoid synovium have been shown to promote onward migration of T cells through the 
endothelial cell layer in co-culture models (44). When T cells are brought in close contact with RA-SFs 
that have been cultured with ECs, migration through cell layers occurs significantly more rapidly than 
when the same experiment is performed with dermal fibroblasts. This difference appears to be 
mediated by the increased production of CXCL12/SDF-1 by the RA-SFs (45).  
 
3.3 Retention of lymphocytes 
The process of generating an adaptive immune response requires well-coordinated and 
precise immune cell migration. Dendritic cells must sample antigen from the site of inflammation, 
then migrate to the draining lymph node to present the antigen to helper T cells. This process 
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requires specific, accurate and timely chemokine gradients to ensure that the immune cells interact at 
the right time, and in the right place. It has been suggested that activated fibroblasts may destabilise 
the physiological chemokine gradients underpinning this process through the upregulation and 
secretion of chemokines which promote retention of lymphocytes at a particular site. (47) 
Leukocyte survival factors such as type 1 interferons, CXCR4 and its ligand CXCL12/SDF-1 
contribute to the retention of lymphocytes as lymphoid aggregates in secondary lymphoid tissue (17, 
57-59). SDF-1/CXCL12 is usually responsible for retention of lymphocytes within the bone marrow. 
Up-regulation of CXCR4 on infiltrating T lymphocytes by stromal derived TGF-β and expression of SDF-
1 has been observed in inflamed synovium, intestine and skin (60, 61). It is also possible that 
fibroblasts imprinted with an inflammatory phenotype fail to switch off production of SDF-1 (17). 
These findings suggest that ‘pro-retention’ factors are important in the maintenance of the chronic 
inflammation; promoting retention of lymphocytes in an area of inflammation and inhibition of 
leukocyte migration minimises disruption. In other words the inflamed microenvironment becomes 
even more stable. 
 
3.4 Tertiary lymphoid organs (TLOs) 
The chemokines and adhesion molecules involved in recruitment of T cells to specific 
anatomical sites in health are well characterised. (46). Naïve T cells display a restricted pattern of 
recirculation, homing only to secondary lymphoid tissue using L-selectin, LFA-1 and the chemokine 
receptor CCR7. Memory T cells, in contrast, migrate to any anatomical site depending on the specific 
pattern of chemokines, receptors and adhesion molecules expressed (47).  
As outlined above, activated fibroblasts undergo epigenetic and phenotypic changes in 
response to chronic inflammation. Activated rheumatoid synovial fibroblasts for example can 
resemble lymphoid fibroblasts when appropriately stimulated for long enough during episodes of 
acute inflammation (8, 33, 47, 48). When the stromal area postcode becomes sufficiently disordered 
in non-infectious/non-antigen specific chronic inflammation, fibroblasts and endothelial cells drive T-
lymphocytes to accumulate at the area of disease and become organised into aggregates with 
structure reminiscent of lymph node structures, termed tertiary lymphoid organs (TLOs). (49). 
TLOs are found in many chronic autoimmune disorders including rheumatoid arthritis, type 1 
diabetes mellitus, Sjogren’s syndrome, Hashimoto’s thyroiditis and Crohn’s disease (16). The 
mechanism for TLO formation has been explored in mouse models of diabetes where the expression 
of the homeostatic/lymphoid chemokine CXCL13 within pancreatic islets causes B cell recruitment 
and lymphoid neogenesis (50). CCL21, a chemokine specific to naïve lymphocytes, when ectopically 
expressed in transgenic mouse models, also leds to accumulation of T cell lymphoid infiltrates (51). 
More recent studies have shown that CXCL13 blockade disrupts B lymphocyte organization in tertiary 
lymphoid structures in non- obese diabetic mice (52). In the rheumatoid synovium, lymphoid-like 
fibroblasts produce CXCL13 and CCL19 driving lymphoid neogenesis (17, 45, 53). CCL19, VCAM-1 and 
ICAM-1 have been shown to play a role in TLO formation (54, 55).  
Lymphoid-like fibroblasts also express Gp38 (podoplanin), a glycoprotein which is expressed 
by cells within areas of healthy, secondary lymphoid tissue (16). In non-lymphoid, physiological 
fibroblasts, gp38 is not expressed.  Upon transformation of fibroblasts into a lymphoid like 
phenotype, gp38 and CD157 (BP-3) become expressed, leading to production of IL-7 and the lymphoid 
cytokines CXCL13 and CCL19 (17, 45, 53). Expression of gp38 has also been detected in various types 
of malignancy. In both malignancy and chronic inflammation, expression of gp38 corresponds with 
disease aggression and poor prognosis (16). Accordingly, it is important to note that the histological 
finding of TLOs in the synovium of patients with early RA is associated with severe disease progression 
and erosive disease (56). 
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3.5 Inhibition of leukocyte apoptosis 
Resolution of an inflammatory response requires the removal of the majority of immune 
cells that were recruited and then proliferated at a site of inflammation. This process involves 
leukocyte emigration from the site of pathology and extensive apoptosis of activated T-cells (58). To 
maintain immunological memory, a few of these T cells must survive the wave of tissue apoptosis. 
The process of T-cell apoptosis at sites of pathology is therefore tightly regulated.  There is now 
strong evidence that this process is stromal cell mediated (58). 
In order to resolve an acute episode of inflammation, active Fas-induced apoptosis of 
leukocytes occurs, limiting the extent of tissue damage and acting as the trigger for the resolution 
phase (62). This process acts in synergy with apoptosis resulting from cytokine deprivation (63). 
In T-cells, IL-2 (predominantly), IL-4, IL-7, IL-9 and IL-15 use a shared receptor signalling 
component which forms the γ chain of the IL-2 receptor (58, 64, 65). When these cytokines are 
withdrawn, T cell apoptosis occurs readily (66). This cytokine-mediated inhibition of apoptosis occurs 
via upregulation of the genes BCl-2 and Bcl-xL and increased T-cell proliferation (64). Cytokine-
deprived T cells in rheumatoid arthritis however may be rescued from apoptosis via interaction with 
RA-SFs (64, 67). This process however, does not involve increased expression of BCl-2 or T-cell 
proliferation (66), suggesting that fibroblast mediated inhibition of T-cell apoptosis occurs via a 
mechanism which is distinct from cytokine deprivation. The NF-κB family of transcription factors 
which is heavily upregulated in the rheumatoid synovium has been implicated in the regulation of bcl-
2 regulated apoptosis (68). Type one interferons, particularly IFN-β, are the predominant factors 
influencing stromal mediated inhibition of apoptosis (58). Our group has proposed therefore, that RA-
SF mediated blockade of lymphocyte death through upregulation of aberrant ‘pro-survival’ 
cytokines/chemokines is a major contributing factor to the persistence of T cell infiltration despite low 
levels of T-cell cytokines in the chronically inflamed rheumatoid synovium (64). 
B-cell survival depends on fibroblast production of IL-6 and expression of CXCL12 (69). 
Expression of the type II membrane proteins; BAFF (B cell activating factor) and APRIL (a proliferation 
inducing ligand) by RA-SFs have been shown to mediate B cell survival and function within the RA 
synovium (70). 
 
3.6 Tissue destruction in RA 
RA-synovial fibroblasts (RA-SFs) within the lining layer of the synovial joint cartilage are 
known to contribute to joint destruction and bony erosions through expression of degradation 
enzymes such as MMPs (71). MMP-2, MMP-9 and MMP-13 have been specifically implicated (72). 
MMP-9 is also upregulated by CXCL12 (SDF-1) (73). Fibroblast activation protein (FAP) is expressed at 
high levels in the lining layer of the synovium, and is co-localised with MMP-13 within the rheumatoid 
synovium (74).  Cathepsins, a major group of proteases, which are involved in joint destruction, have 
also been shown to be upregulated in the rheumatoid synovium (75). When RA-SFs are transfected 
with the ras proto-oncogene, cathepsin L is upregulated (76). The pro-inflammatory cytokines IL-1, IL-
6 and TNFα also stimulate the production of cathepsins; an effect mediated by RA-SFs (77). 
 
3.7 p21 cyclin dependent kinase inhibitors (CDKi) 
Cyclin dependent kinases (CDKs) are primarily responsible for regulation of the cell cycle. 
CDKi overexpression induces cell cycle arrest (78). p21, a CDKi has been shown to inhibit arthritis 
development in mouse models (79). The expression of p21 by synovial fibroblasts is reduced in 
isolated RA-SFs compared to OA synovial fibroblasts (80). In p21-deficient synovial fibroblasts in mice, 
a 100-fold increase in IL-6 protein and enhanced IL-6 mRNA is seen (80). Overexpression of MMPs and 
cathespins has also been noted in p21 deficient mice (81) thus suggesting a protective, anti-
inflammatory role for p21 CDKi in RA.  
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Table 2: Fibroblast mediated persistence of chronic inflammation 
*Low levels of BCl-2 are observed during fibroblast mediated inhibition of lymphocyte apoptosis. All 
other molecules are up regulated by fibroblasts to modulate persisting inflammation. ^Increase 
survival of B-cells. 
 
 
3.8 The synovium in patients with early rheumatoid arthritis 
The model of persistent inflammation in RA proposed above requires the presence of 
lymphoid aggregates and a hyperplastic synovium. These features are rare in patients with active 
synovitis in the early stages of the disease. It is therefore likely that the pathological mechanisms 
underpinning disease initiation are distinct from those causing disease persistence. Additionally the 
observation that spontaneous remission is unusual when an inflammatory arthritis has persisted for 
longer than 6 months (82) suggests that the stromal-mediated processes, as outlined above, are well 
established by this time. In support of this idea is the finding that the cytokine/chemokine profile in 
the synovial fluid of patients with early (less than 12 weeks onset) synovitis who were likely to 
subsequently progress to persistent RA was distinct from synovial fluid from the same patient cohort 
who were unlikely to progress to established RA (83).  The early synovial cytokine/chemokine profile 
from patients who were likely to develop RA demonstrated high levels of T-cell, macrophage and 
stromal derived cytokines (IL-2, IL-4, IL-13, IL-17, IL-1, IL-15, bFGF and EGF). This profile is transient 
and is not present in the synovium of patients with persistent disease. These findings suggest that the 
type of immune response that leads to RA involves stromal components and Th2 cytokines and is 
likely to influence the biology of the tissue microenvironment required for persistent disease (83).  
 
4.0 Biological agents in RA that target the stroma 
Cytokine inhibition using biological therapies has revolutionized the management of 
rheumatoid arthritis in recent years. Despite the successes of this approach, we are still unable to 
cure the disease. Most therapies share a maximum therapeutic response rate of around 20% 
achieving an ACR 70 response (15). As we have outlined, stromal derived cytokines such as IL-1, IL-6 
and TNFα are intermediate effectors of the autoimmune response in RA. It is therefore not surprising 
that their blockade dampens inflammation as opposed to eliminating it. In this review we have 
outlined that stromal elements, in particular fibroblasts, act upstream of these cytokines and are 
Recruitment TLO formation Retention Reduced emigration Reduced apoptosis 
IL-1 gp38 IFN-1 CXCL12 (SDF-1) Bcl-xL 
IL-6 CD157 (BP-3) IL-15 CCL21 BCl-2* 
TNFα IL-7 BAFF  IFN-β 
COX-2 CXCL13 (BLC) CXCL12 (SDF-1)  NF-κB 
CXCL8/IL-8 CCL19 CXCR4  IL-2 
CCL5 CCL21 (SLC) TGF-β  IL-4 
CXCL1 ICAM-1   IL-15 
CXCR2 VCAM-1   BAFF^ 
CXCL5    APRIL^ 
CXCL12 (SDF-1)    IL-6^ 
    CXCL12^ (SDF-1) 
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responsible for the persistence of chronic inflammation in rheumatoid arthritis. There are however, at 
present, no therapeutic agents available which directly target the fibroblasts, nor are there agents 
which target the potent fibroblast-effectors modulating persistence (TLO formation, pro-retention 
factors and pro-survival factors). However, conventional biologics do have effects on the stroma and 
their cellular products. For example Tocilizumab, which targets IL-6, has anti stromal effects. In active 
rheumatoid arthritis, IL-6 is found in abundance in both the synovium and the circulation (32). Within 
the inflamed synovium, IL-6 is produced by activated synovial fibroblasts and is pro-inflammatory. 
Downstream pro-inflammatory effects include stimulation of differentiation of B cells into 
immunoglobulin secreting plasma cells, activation of T cells (84), promotion of B-cell survival (69), and 
the recruitment of neutrophils and lymphocytes (32, 42, 43). IL-6 also contributes to joint destruction 
by interaction with cathepsins (77). 
 
 4.1 Possible future stromal targets 
Cellular MAPK and NF-κB pathways are heavily implicated in the inhibition of T cell apoptosis 
in the rheumatoid synovium. These pathways however are generic; involved in directing the cellular 
responses in numerous cellular systems. More specific MAPK effectors are therefore being targeted, 
of which p38 MAPKinases which share similarities with the janus kinase pathway are known to impact 
on synovial fibroblast biology (86).  
Fibroblasts express a number of sensitive, but non-specific markers (Table 1). Targeting 
pathogenic fibroblasts alone, without collateral damage, is therefore a challenge. Research is 
currently underway to identify pathogenic fibroblast markers. Cadherin-11 is both a sensitive 
fibroblast marker and is relatively specific to the inflammatory synovium in mouse models of arthritis. 
Cadherin-11 promotes invasive behaviour of RA-SFs (87). Its high specificity to pathological states 
makes it an attractive potential target for further investigation. CD248 is a similar fibroblast target, 
which has a role in adhesion and its blockade in mouse models of arthritis has been promising (88). 
RA-SFs express low levels of the p21 CDKi, translating to a pro-inflammatory effect mediated by IL-6 
(80). Adenovirus mediated p21 gene transfer to RA-SFs is currently under investigated to treat RA in 
early clinical trials. Finally, blockade of CXCR4, the receptor for CXCL12/SDF-1 using the antagonist 
AMD3100 in mouse models of arthritis has shown significant reduction in disease severity (89) In 
human trials however, its use has been abandoned due to its adverse effects including bone marrow 
suppression (15). 
 
 
5.0 Conclusions 
Fibroblasts play a role in regulating the accumulation of leucocytes in inflamed tissues. In 
response to recurrent inflammatory stimuli, fibroblasts undergo phenotypic alterations, which alter 
their pathogenic potential. These alterations are very specific and contextual. In the case of 
inflammatory states such as rheumatoid arthritis, the fibroblast phenotype changes to one which 
behaves like a lymphoid fibroblast; supporting leukocyte adhesion and migration, lymphoid 
neogenesis, retention of leukocytes and inhibition of leukocyte apoptosis. All of these promote 
persistent and stable inflammation within the synovium.  
Currently available biologic agents for use in rheumatoid arthritis do not directly target the 
fibroblast but do target their cell products (eg IL-6), which mediate persistence of inflammation. As 
such, current available therapies for rheumatoid arthritis do not truly target the persistence of 
inflammation. Novel therapeutic agents directed at tissue resident stromal cells and which aid their 
depletion offers an exciting new avenue of research. These agents may turn out to be the key to the 
cure of persistent inflammatory disorders such as rheumatoid arthritis.  
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6.0 Practice points 
• IL-1, IL-6 and TNFα blockade is useful to suppress persistent disease activity in patients with 
rheumatoid arthritis 
• Future targeting of stromal pathways involved in the switch of acute to chronic inflammation 
(gp38, CXCR4) may be useful to prevent persistent synovitis and joint destruction in patients 
with early (<12 weeks) synovitis 
 
 
7.0 Research Agenda 
• Continued search for more specific fibroblast markers 
• Data on the use of novel fibroblast targeted agents/genetic therapies for use in chronic 
inflammatory conditions 
• Targeting epigenetic modifications to alter RA-SF phenotype 
• Development of a unified understanding of the immunopathogenesis of rheumatoid arthritis, 
with particular focus on the immune mechanisms underpinning the switch from resolving to 
persistent inflammation to guide research into more novel targets that may be used to 
prevent rheumatoid arthritis in patients with early synovitis who are at significant risk of 
developing persistent disease. 
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